Myomo, Inc. MYO R2K
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 38.1% over 5 years.
CONS
- Earnings shrank at -15.1% CAGR over 5 years.
- Trading 63.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MYO Myomo, Inc. R2K | 1.09 | - | $42.12M | - | -48.26% | -98.53% | 38.05% | -15.09% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 313.18K | 632.37K | 608.98K | 830.07K | 880.35K | 606.62K | 1.01M | 858.59K | 1.93M | 2.34M | 3.10M | 4.38M | 3.87M | 3.68M | 3.97M | 3.45M | 5.96M | 5.08M | 3.75M | 7.52M | - | - | 9.83M | 9.65M | 10.09M | 11.35M | 10.11M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.22M | 3.60M | 3.65M | 3.57M | 3.21M |
| Gross Profit | 203.88K | 107.11K | 137.66K | 208.04K | 364.44K | 205.10K | 431.92K | 415.40K | 543.26K | 500.26K | 277.39K | 689.49K | 439.73K | 1.07M | 1.71M | 2.20M | 3.27M | 2.58M | 2.40M | 2.64M | 2.31M | 4.28M | 3.49M | 2.30M | 5.33M | - | - | 6.61M | 6.05M | 6.44M | 7.78M | 6.90M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.13M | 10.64M | 9.96M | 10.56M | 10.06M |
| Operating Income | -688.58K | -933.83K | -1.36M | -1.93M | -1.43M | -2.40M | -2.68M | -2.71M | -2.68M | -2.71M | -2.83M | -3.42M | -2.85M | -2.55M | -2.93M | -2.60M | -2.03M | -2.74M | -2.90M | -2.82M | -2.67M | -1.10M | -2.02M | -3.89M | -1.12M | - | - | -3.52M | -4.59M | -3.52M | -2.77M | -3.16M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.07M | -4.16M | -3.08M | -2.32M | -2.69M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.33M | -4.48M | -3.53M | -3.73M | -2.82M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 136.79K | 148.20K | 135.66K | 83.88K | 186.72K |
| Net Income | -759.89K | -1.02M | -1.56M | -7.38M | -1.26M | -2.35M | -2.63M | -2.65M | -2.60M | -2.57M | -2.79M | -3.80M | -3.29M | -2.78M | -2.96M | -2.62M | -2.06M | -2.81M | -2.91M | -2.83M | -2.64M | -1.01M | -2.03M | -3.84M | -1.12M | - | - | -3.47M | -4.63M | -3.66M | -3.81M | -3.01M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.46 | -0.36 | -0.41 | -0.42 | -0.40 | -0.11 | -0.04 | -0.06 | -0.10 | -0.03 | - | - | -0.08 | -0.11 | -0.09 | -0.09 | -0.07 |
| R&D Expense | 258.28K | 237.69K | 356.88K | 708.62K | 329.36K | 372.36K | 486.98K | 449.67K | 446.35K | 427.57K | 433.06K | 506.95K | 397.81K | 345.67K | 525.97K | 600.12K | 641.23K | 659.54K | 632.87K | 690.41K | 476.99K | 564.24K | 717.26K | 956.22K | 1.01M | 1.25M | - | 1.79M | 2.00M | 1.53M | - | 1.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 2.44M | 3.84M | 7.58M | - | 15.56M | 19.24M | 32.55M | 40.93M |
| Cost of Revenue | - | - | - | - | - | - | 5.30M | 6.06M | 9.37M | 14.04M |
| Gross Profit | 821.11K | 1.05M | 1.72M | 2.42M | 4.98M | - | 10.25M | 13.18M | 23.19M | 26.89M |
| Operating Expenses | - | - | - | - | - | - | 20.93M | 21.41M | 29.39M | 41.29M |
| Operating Income | -3.28M | -6.55M | -10.53M | -10.80M | -10.50M | - | -10.67M | -8.23M | -6.21M | -14.40M |
| EBITDA | - | - | - | - | - | - | -10.13M | -7.71M | -5.43M | -12.64M |
| Interest Expense | - | - | - | - | - | 15.34K | - | - | - | 450.83K |
| Pretax Income | - | - | - | - | - | - | -10.65M | -7.99M | -5.82M | -15.07M |
| Tax Provision | - | - | - | - | - | - | 69.94K | 156.00K | 365.62K | 504.53K |
| Net Income | -3.62M | -12.10M | -10.32M | -10.71M | -11.56M | - | -10.72M | -8.15M | -6.18M | -15.57M |
| Diluted EPS | - | - | - | - | - | - | -1.52 | -0.28 | -0.16 | -0.37 |
| R&D Expense | 1.12M | 1.75M | 1.84M | 1.75M | 1.67M | 2.56M | 2.48M | 2.64M | 4.77M | 6.94M |
Compounded Sales Growth
| 5 Years: | 38.05% |
| 1 Year: | 2.90% |
Compounded Profit Growth
| 5 Years: | -15.09% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -63.30% |
| 6 Months: | +30.07% |
| 3 Months: | +40.65% |
| 1 Month: | +37.63% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.66M | 13.97M | 8.28M | 6.60M | 14.71M | - | 10.16M | 14.58M | 42.24M | 38.64M |
| Current Assets | - | - | - | - | - | - | - | 9.22M | 13.65M | 32.79M | 27.56M |
| Cash & Equivalents | 1.04M | 797.17K | 12.96M | 6.54M | 4.47M | 12.24M | - | 5.35M | 6.87M | 24.37M | 14.13M |
| Inventory | - | - | - | - | - | - | - | 1.40M | 1.80M | 3.17M | 3.12M |
| Receivables | - | - | - | - | - | - | - | 1.90M | 2.38M | 3.83M | 4.10M |
| Total Liabilities | - | 6.52M | 1.53M | 1.86M | 4.77M | 3.14M | - | 3.80M | 5.59M | 17.53M | 27.23M |
| Current Liabilities | - | 3.00M | 1.49M | 1.86M | 3.88M | 2.87M | - | 3.60M | 5.48M | 10.17M | 8.35M |
| Long Term Debt | - | - | - | - | 888.96K | - | - | - | - | - | 11.22M |
| Total Debt | - | - | - | - | - | - | - | 553.91K | 601.30K | 8.11M | 19.38M |
| Total Equity | -13.90M | -17.53M | 12.45M | 6.43M | 6.43M | 11.57M | - | 6.36M | 8.99M | 24.71M | 11.40M |
| Shares Outstanding | - | - | - | - | - | - | - | 7.75M | 27.14M | 34.38M | 38.47M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.20M | -6.15M | -9.61M | -10.34M | -9.03M | - | -10.23M | -6.17M | -3.29M | -14.51M |
| Investing Cash Flow | -1.86K | -67.00K | -126.87K | -51.99K | -45.75K | - | -310.79K | -2.03M | 259.98K | -7.06M |
| Financing Cash Flow | 2.96M | 18.38M | 3.34M | 8.32M | 16.78M | - | 376.86K | 9.71M | 20.93M | 11.43M |
| Capital Expenditure | -1.86K | -67.00K | -126.87K | -51.99K | -45.75K | - | -111.79K | -145.82K | -1.36M | -3.33M |
| Free Cash Flow | -3.20M | -6.22M | -9.73M | -10.39M | -9.08M | - | -10.35M | -6.32M | -4.65M | -17.84M |
| Net Change in Cash | - | - | - | - | - | - | -10.17M | 1.51M | 17.90M | -10.14M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 70.2% | 63.0% | 65.7% | - | 65.9% | 68.5% | 71.2% | 65.7% |
| Operating Margin % | - | - | -430.8% | -281.3% | -138.5% | - | -68.6% | -42.8% | -19.1% | -35.2% |
| Net Margin % | - | - | -422.1% | -279.1% | -152.5% | - | -68.9% | -42.3% | -19.0% | -38.1% |
| ROE % | 20.6% | -97.2% | -160.5% | -166.7% | -100.0% | - | -168.6% | -90.6% | -25.0% | -136.6% |
| ROCE % | 243.8% | -52.4% | -163.8% | -397.6% | -88.7% | - | -162.7% | -90.4% | -19.4% | -47.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Rosalind Advisors, Inc. | 9.96% | 3.85M | $4.19M |
| 2 | Blackrock Inc. | 4.37% | 1.69M | $1.84M |
| 3 | Vanguard Capital Management LLC | 2.96% | 1.14M | $1.25M |
| 4 | Geode Capital Management, LLC | 2.22% | 858.80K | $936.09K |
| 5 | Jefferies Financial Group Inc. | 1.82% | 704.27K | $767.66K |
| 6 | Clearstead Advisors, LLC | 1.10% | 425.60K | $463.90K |
| 7 | State Street Corporation | 0.99% | 383.19K | $417.68K |
| 8 | Nuveen, LLC | 0.96% | 370.32K | $403.65K |
| 9 | AQR Capital Management, LLC | 0.83% | 318.95K | $347.66K |
| 10 | UBS Group AG | 0.81% | 311.72K | $339.77K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MYO